Ibrutinib as a single agent or in combination with rituximab or obinutuzumab or venetoclax
is indicated for the treatment of adult patients with previously untreated chronic lymphocyticleukaemia (CLL)
Ibrutinib as a single agent or in combination with bendamustine and rituximab (BR) isindicated for the treatment of adult patients with CLL who have received at least one priortherapy.
Ibrutinib as a single agent is indicated for the treatment of adult patients with Waldenström"smacroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatmentfor patients unsuitable for chemoimmunotherapy.
Ibrutinib in combination with rituximab is indicated for the treatment of adult patients withWM.
Crohn’s Disease:
Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.
Ulcerative colitis:
Ustekinumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
Famotidine Injection is intended for the following indications:
• Short term treatment of active duodenal ulcer.
• Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
• Short term treatment of active benign gastric ulcer.
• Short term treatment of gastroesophageal reflux disease (GERD).
Treatment of pathological hypersecretory conditions.
Acyclovir is indicated for the treatment of Herpes Simplex virus
infections of the skin including initial and recurrent genital herpes and herpes labialis.
Type 2 diabetes mellitus
Dapagliflozin is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
-as monotherapy when metformin is considered inappropriate due to intolerance.
-in addition to other medicinal products for the treatment of type 2 diabetes.
Heart failure
Dapagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure.
Chronic kidney disease
Dapagliflozin is indicated in adults for the treatment of chronic kidney disease.
Type 2 diabetes mellitus
Dapagliflozin is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
-as monotherapy when metformin is considered inappropriate due to intolerance.
-in addition to other medicinal products for the treatment of type 2 diabetes.
Heart failure
Dapagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure.
Chronic kidney disease
Dapagliflozin is indicated in adults for the treatment of chronic kidney disease.
For adult patients with type 2 diabetes mellitus:
as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.
as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
